Healthcare companies chase cures and capital in South Florida
Leaders of hundreds of public healthcare companies are in South Florida this week, talking up their innovations and financial performances to attract and impress investors at the Goldman Sachs Global Healthcare Conference.
Consumers will find that nearly every disease or ailment they suffer from has a treatment in development, as big and small companies see opportunities in Americans' desire to live longer and pain-free. From new devices for sleep apnea to drugs for cancer, to creams for chronic itching and drops for improved eyesight, advances are underway that hold promise.
Presenters like LENZ Therapeutics wowed the audience on Monday with product updates, such as an eyedrop that lasts all day and allows for close-up vision, which most people use reader glasses to achieve. The eye drops target a market of over 128 million people in the U.S. who need help with near vision.
This year, new factors are affecting how quickly consumers can obtain a drug or device to improve or save their lives, according to company executives. The uncertainty in Washington, D.C., looms large. Policy turbulence, regulatory uncertainty, shakeups at health agencies and President Donald Trump's aggressive stance on drug pricing and tariffs factor into the future for the devices and treatments working their way toward the marketplace.
Anti-Trump protests will unfold across South Florida this weekend. Here's what to expect
Top RFK Jr. aide attacks US health system while running company that promotes wellness alternatives
Hidden charges? Patients often face massive bills when Florida hospitals don't provide costs upfront
Native Americans hurt by federal health cuts, despite RFK Jr.'s promises of protection
Georgia's experience raises red flags for Medicaid work requirement moving through Congress
'This year, the biggest questions we are opening with for all of our companies is the policy calculus in Washington, D.C., and how that could play out across the healthcare sector,' said Asad Haider, Goldman Sachs' head of the healthcare business unit within Global Investment Research and the lead analyst for the U.S. pharmaceuticals sector. 'The starting point in all these presentations is give us the landscape on where things could go with respect to what's going on in Washington, D.C.'
Over 200 top managerial teams attended the conference, representing every corner of the healthcare field, from major pharmaceutical companies to small biotech firms. The goal of the three-day conference was to provide institutional investors with insights into companies' business plans, data, and progress, particularly at a strategic mid-year point.
Innovation hotspots this year include treatments for weight loss, with a focus on oral drugs replacing injectables and medications to help maintain a healthy weight. Another is oncology, immunology, and neuroscience with breakthroughs to detect diseases earlier and find new drug delivery methods. Several companies at the conference have formed partnerships with companies across the globe to access new markets, technologies, and expertise.
China is emerging as a global leader in biotechnology, with numerous U.S. and European companies collaborating with or licensing technologies from Chinese companies. Summit Therapeutics, a Miami-based company, drew interest at the conference with its innovative cancer-fighting, bispecific antibody, ivonescimab, and its partnership with a Chinese laboratory. Ivonescimab has shown promise in previous trials in China and additional trials are underway combining the drug with chemotherapy to target non-small-cell lung cancer.
'We have over 22 or 23 different trials going on or completed or going to start,' said Maky Zangaheh, co-CEO of Summit Therapeutics. 'One element of that is a phase 3 trial that China and us are combining with over 3,000 patients enrolled, so we will have a good safety profile and efficacy profile in many different therapeutic areas. From a commercialization point of view, we are already in China and have two Chinese approvals, which is significant progress.'
Doron Junger, of Sanvia Capital, a South Florida biotech investment firm, said he attended the conference looking to invest in companies developing innovations that could address large or niche markets in a more meaningful way. A few have caught his attention; however, he is cautious about those who tout therapies in their pipelines.
'More drug trials fail than succeed, and while there is a lot of innovation in this industry in areas of need like oncology and chronic diseases, even at a late stage, there is potential for a clinical trial to fail to show an advantage over a placebo group,' he said. 'Even if it does, that trial has to pass muster with the rigorous standards the FDA sets for approval.'
On Monday, Arcturus Therapeutics of San Diego presented an update on a daily inhaled treatment for Cystic Fibrosis, which could be a breakthrough for the disease. Additionally, BioAge Labs CEO Kristen Fortney explained how her California company uses samples from a repository to study the biology of human aging and develop new therapies for obesity. Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space and believes it can improve upon oral therapies now on the market, she said.
'More and more people are aging, and by definition, they are using more healthcare,' said Haider of Goldman Sachs. 'The aging population is going to need new drugs, better drugs, faster drugs for diabetes and cardiometabolics and oncology and all of these diseases that potentially could kill you. There will be innovation, but what are we willing to pay for that innovation?'
Will regulations make it more difficult and/or costly for people to access the devices and drugs that can save their lives? Haider said drug pricing will be a key concern for both consumers and investors. 'Everyone is chasing big caps, big targets, but there will be winners and losers.'
South Florida Sun Sentinel health reporter Cindy Goodman can be reached at cgoodman@sunsentinel.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
an hour ago
- The Hill
‘The Pitt's' Noah Wyle tells Congress: Health care workers are facing a ‘crisis'
He plays a doctor on TV, but Noah Wyle is making a pitch for real-life health care workers at the Capitol, meeting with lawmakers about legislation addressing burnout, mental health and more. 'I've spent the bulk of my adult life playing an emergency room physician, but I am here today with the people who really do the work for a living, and to share some of the pressures and struggles that they're facing,' Wyle, who stars as Dr. Michael 'Robby' Robinavitch on Max's 'The Pitt,' said as he led a panel discussion on Thursday at the Cannon House Office Building. 'Health care professionals today are navigating chronic understaffing. They are losing hours to red tape and administrative tasks. Many are facing mental health struggles with limited institutional support and financial pressure that makes it feel impossible to stay. It's not sustainable,' Wyle, 54, said. He said that growing up with a mom who worked as a registered nurse gave him an 'up close and personal look at how demanding this job can be. And I've learned in recent years how much harder this job has become.' The 'ER' alum's mom, Marjorie Speer, joined her son along with more than a dozen health care workers at the event. Wyle, who came to Washington with the health care apparel company, FIGS, was poised to meet with lawmakers to urge them to reauthorize the Dr. Lorna Breen Health Care Provider Protection Act. The bill's proponents say it would help support the mental health of frontline health care providers through federal programs and training and would reduce the risk of suicide and burnout. 'This is not a workforce issue. This is a patient health care issue. This is a national health care crisis, and that is why we are here: To listen, and to learn and to talk about what can change when we take these stories seriously and work together constructively on them in a bipartisan way,' the actor said. 'Because if we don't have a healthy and functioning health care workforce, we don't have health care at all,' Wyle said. Rep. Buddy Carter (R-Ga.), who noted that he was one of two pharmacists in Congress, told the group, 'I've seen health care. I've seen it firsthand, and I've seen the stress. I've seen the work that goes into health care, and the work and the stress that health care workers have, and it's something that needs to be addressed.' 'When it comes down to it, whether you're Republican, or Democrat or independent, we all want the same thing when it comes to health care: We want accessible, affordable, quality health care,' Carter said. 'We've got to be there, and we've got to make sure that we take the stigma out of this situation and that we enable people to seek help that they need,' Sen. Tim Kaine (D-Va.) said, mentioning he's faced his 'own little journey in this [health care] space' for the last five years after being diagnosed with long COVID-19. Asked if it was harder to play a doctor on the small screen or to press lawmakers in a divided Congress to pass legislation, Wyle told ITK with a grin, 'This is definitely more fun.' 'This is an incredible opportunity to come to Washington to be an advocate and sit on this panel with these people — it's an incredible honor for me,' he said, adding he was especially grateful to share the experience with his mom. 'I think my day job is harder and this is more rewarding,' he said. During a more lighthearted moment, Wyle also divulged which lawmaker he'd want to play. 'I don't want to pick favorites here,' the Emmy-nominated performer told ITK, before saying matter-of-factly, 'Abraham Lincoln.' Someone in the crowd exclaimed in response: 'You've got the beard for it!'
The Hill
an hour ago
- The Hill
CDC backtracks, will rehire more than 450 people it laid off
The Centers for Disease Control and Prevention (CDC) is rehiring about 460 employees who had previously been laid off, according to an email notice reviewed by The Hill. The Department of Health and Human Services (HHS) confirmed on Thursday that reinstatement notices were sent, but provided few other details. 'The Trump Administration is committed to protecting essential services—whether it's supporting coal miners and firefighters through [the National Institute for Occupational Safety and Health], safeguarding public health through lead prevention, or researching and tracking the most prevalent communicable diseases,' HHS said in a statement to The Hill. 'HHS is streamlining operations without compromising mission-critical work. Enhancing the health and well-being of all Americans remains our top priority.' Thank you for signing up! Subscribe to more newsletters here Fox News first reported that the CDC was rehiring hundreds of workers fired from multiple areas within the agency. Rehired workers are from four different operational divisions within the CDC: the National Center for HIV, Viral Hepatitis, STD, and Tuberculosis Prevention; the National Center for Environmental Health; the Immediate Office of the Director, and the Global Health Center. The workers were initially fired as part of a broad reorganization and downsizing as HHS cut as many as 10,000 jobs across various health agencies. About 2,400 employees were laid off at the CDC. Among those reinstated are about 160 employees at the CDC's National Center for Environmental Health, including people who fought childhood lead exposure and those who worked on cancer clusters. According to the email seen by The Hill, the agency said it 'revoked' the 'upcoming reduction in force' notices the workers had previously received, without explanation. In April, HHS Secretary Robert F. Kennedy Jr. acknowledged that about 20 percent of the layoffs at HHS were a mistake and the plan was always for people to be rehired.
Yahoo
2 hours ago
- Yahoo
M&A to play ‘important role' at Teladoc: CEO
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter. Mergers and acquisitions should play an 'important role' in Teladoc's future business strategy, the virtual care firm's CEO said Wednesday. 'We're going to make investments not just for the short term, but things that we think are going to start to increase that [total addressable market], start to increase the scope and range of what we can do. And we think that's the right place to deploy our capital,' CEO Chuck Divita said at the Goldman Sachs Global Healthcare Conference. The telehealth company has already completed two acquisitions this year, scooping up preventive care firm Catapult Health in February and virtual mental health provider UpLift last month. Teladoc plans to be balanced on capital spending between investments within the firm — like spending on data and analytics and improving customer engagement with its suite of virtual care products — and external growth, including M&A, CFO Mala Murthy said Wednesday. Potential targets for M&A would focus on tuck-ins that could improve patient engagement, buys that would 'expand the aperture in terms of services' and international additions, Murthy said. Expanding the firm's reach in other countries has been a priority for the telehealth vendor. 'It's always going to be strong strategic rationale, and it has to make sense for us in terms of driving our top-line growth on a sustained basis,' Murthy said. 'That's essentially what we'd be looking for.' Teladoc has already made acquisitions under Divita's tenure as CEO, which began a year ago. Buying Catapult, which offers a virtual annual exam with an in-home diagnostic kit, should allow Teladoc to catch members' health conditions early and funnel them toward its other offerings, like chronic condition management programs, executives said earlier this year. Meanwhile, the UpLift deal aims to speed the company's ability to accept insurance coverage for care delivered by its direct-to-consumer mental health segment, BetterHelp. The unit has struggled recently, and its adjusted earnings before interest, taxes, depreciation and amortization was cut in half in the first quarter. Cost is one barrier to getting customers to subscribe to the service, an area where accepting insurance could help, management said. Recommended Reading Teladoc to acquire virtual care company Catapult Health for $65M Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
